Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Theophylline for COPD.

Literature DB >> 16936233

Theophylline for COPD.

P J Barnes.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2006 PMID： 16936233 PMCID： PMC2117081 DOI： 10.1136/thx.2006.061002

Source DB: PubMed Journal: Thorax ISSN： 0040-6376 Impact factor: 9.139

× No keyword cloud information.

14 in total

Review 1. Theophylline: new perspectives for an old drug.

Authors: Peter J Barnes
Journal: Am J Respir Crit Care Med Date: 2003-03-15 Impact factor: 21.405

2. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways.

Authors: M Ichinose; H Sugiura; S Yamagata; A Koarai; K Shirato
Journal: Am J Respir Crit Care Med Date: 2000-08 Impact factor: 21.405

3. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression.

Authors: Kazuhiro Ito; Sam Lim; Gaetano Caramori; Borja Cosio; K Fan Chung; Ian M Adcock; Peter J Barnes
Journal: Proc Natl Acad Sci U S A Date: 2002-06-17 Impact factor: 11.205

4. Inhibition of reactive nitrogen species production in COPD airways: comparison of inhaled corticosteroid and oral theophylline.

Authors: T Hirano; T Yamagata; M Gohda; Y Yamagata; T Ichikawa; S Yanagisawa; K Ueshima; K Akamatsu; M Nakanishi; K Matsunaga; Y Minakata; M Ichinose
Journal: Thorax Date: 2006-09 Impact factor: 9.139

5. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease.

Authors: Sarah V Culpitt; Carmen de Matos; Richard E Russell; Louise E Donnelly; Duncan F Rogers; Peter J Barnes
Journal: Am J Respir Crit Care Med Date: 2002-05-15 Impact factor: 21.405

6. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease.

Authors: D K Kirsten; R E Wegner; R A Jörres; H Magnussen
Journal: Chest Date: 1993-10 Impact factor: 9.410

Review 7. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase.

Authors: Peter J Barnes; Kazuhiro Ito; Ian M Adcock
Journal: Lancet Date: 2004-02-28 Impact factor: 79.321

8. Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration.

Authors: K Ito; T Hanazawa; K Tomita; P J Barnes; I M Adcock
Journal: Biochem Biophys Res Commun Date: 2004-02-27 Impact factor: 3.575

Review 10. Theophylline.

Authors: Peter J Barnes
Journal: Pharmaceuticals (Basel) Date: 2010-03-18

Theophylline for COPD.

Review 1. Theophylline: new perspectives for an old drug.

2. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways.

3. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression.

4. Inhibition of reactive nitrogen species production in COPD airways: comparison of inhaled corticosteroid and oral theophylline.

5. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease.

6. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease.

Review 7. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase.

8. Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration.

9. Effect of low-dose theophylline on airway inflammation in COPD.

10. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages.

1. The Study of Efficacy, Tolerability and Safety of Theophylline Given Along with Formoterol Plus Budesonide in COPD.

2. Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential.

Review 3. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations.

Review 4. The efficacy and safety of cilomilast in COPD.

5. Increased FKBP51 in induced sputum cells of chronic obstructive pulmonary disease patients after therapy.

6. Nanosized rods agglomerates as a new approach for formulation of a dry powder inhaler.

7. Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations.

Review 8. Pharmacological treatment of chronic obstructive pulmonary disease.

Review 9. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease.

Review 10. Theophylline.